ODTX Stock Forecast & Price Target

Odyssey Therapeutics is viewed favorably because OD-001 has already de-risked its core thesis in Phase 2a, meeting the primary endpoint with a 2.6-point mMS reduction and showing 27% clinical remission versus about 10% historic placebo, while remaining clean on safety with no Grade 3+ TEAEs, SAEs, DLTs, or liver signals. The durability of benefit in AT-experienced patients, where remission was 25% despite typically lower outcomes in refractory disease, supports the idea that its upstream RIPK2 scaffolding mechanism can overcome limitations of current downstream immunotherapies and work well as a combination backbone. Financially, the company’s balance sheet also looks supportive, with $216.6MM of cash, cash equivalents, and marketable securities at year-end 2025, preliminary cash of $175.7MM in 1Q26, and expected runway into 2H28, while the broader pipeline and Janssen collaboration add meaningful optionality.

Odyssey Therapeutics is viewed negatively because its value depends on highly uncertain clinical programs in novel immune targets, where efficacy may fall short, statistical significance may not be achieved, or safety signals could emerge and halt development. The company remains precommercial, with OD-001 only in Phase 2a/b, an estimated GAAP net loss until 2034, 3Q26 GAAP EPS of ($1.13), 2026 GAAP EPS of ($6.13), and roughly 48M shares outstanding post-IPO. Its balance sheet and operating profile also imply heavy funding needs, with about $1.3B in additional capital assumed through 2040 and runway into 2028, while commercialization faces entrenched competition from biologics and better-established therapies.